Nothing Special   »   [go: up one dir, main page]

MXPA03000966A - Agentes antidiabeticos. - Google Patents

Agentes antidiabeticos.

Info

Publication number
MXPA03000966A
MXPA03000966A MXPA03000966A MXPA03000966A MXPA03000966A MX PA03000966 A MXPA03000966 A MX PA03000966A MX PA03000966 A MXPA03000966 A MX PA03000966A MX PA03000966 A MXPA03000966 A MX PA03000966A MX PA03000966 A MXPA03000966 A MX PA03000966A
Authority
MX
Mexico
Prior art keywords
antidiabetic agents
antidiabetic
agents
Prior art date
Application number
MXPA03000966A
Other languages
English (en)
Inventor
Ronald Bruce Gammill
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA03000966A publication Critical patent/MXPA03000966A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D321/00Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02Seven-membered rings
    • C07D321/10Seven-membered rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MXPA03000966A 2002-02-28 2003-01-31 Agentes antidiabeticos. MXPA03000966A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36091302P 2002-02-28 2002-02-28

Publications (1)

Publication Number Publication Date
MXPA03000966A true MXPA03000966A (es) 2003-09-04

Family

ID=27734776

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000966A MXPA03000966A (es) 2002-02-28 2003-01-31 Agentes antidiabeticos.

Country Status (8)

Country Link
US (2) US6821977B2 (es)
EP (1) EP1340500A1 (es)
JP (1) JP2004002311A (es)
AU (1) AU2003206028A1 (es)
BR (1) BR0300314A (es)
CA (1) CA2419685A1 (es)
MX (1) MXPA03000966A (es)
WO (1) WO2003072570A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2445944A1 (en) * 2001-05-04 2002-11-14 Pfizer Products Inc. Method of preventing type 2 diabetes with aerosolized insulin
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
BR0316099A (pt) * 2002-11-07 2005-09-27 Pfizer Prod Inc Agentes antidiabéticos
CA2515368A1 (en) 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
WO2005007628A1 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
EP1866298A2 (en) * 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
KR20080012304A (ko) * 2005-05-23 2008-02-11 니뽄 다바코 산교 가부시키가이샤 피라졸 화합물 및 이들 피라졸 화합물을 포함하여이루어지는 당뇨병 치료약
US20080076742A1 (en) * 2005-10-31 2008-03-27 Wisconsin Alumni Research Foundation Methods and compositions for treating diseases associated with neovascualrization
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2008062739A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Pyrazoles et leur utilisation en tant que médicaments
ES2537529T3 (es) 2008-06-05 2015-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Novedosos moduladores de la señalización de proteínas cinasas
WO2013166588A1 (en) 2012-05-08 2013-11-14 Bitstrips Inc. System and method for adaptable avatars
EP3021944B1 (en) 2013-07-14 2018-12-19 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
CN107250108B (zh) 2015-02-05 2020-11-27 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
US10339365B2 (en) 2016-03-31 2019-07-02 Snap Inc. Automated avatar generation
WO2018073828A1 (en) 2016-10-20 2018-04-26 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Dna primase and gyrase inhibitors
US10432559B2 (en) 2016-10-24 2019-10-01 Snap Inc. Generating and displaying customized avatars in electronic messages
US10593116B2 (en) 2016-10-24 2020-03-17 Snap Inc. Augmented reality object manipulation
US10242503B2 (en) 2017-01-09 2019-03-26 Snap Inc. Surface aware lens
US10242477B1 (en) 2017-01-16 2019-03-26 Snap Inc. Coded vision system
WO2018201104A1 (en) 2017-04-27 2018-11-01 Snap Inc. Regional-level representation of user location on a social media platform
US11122094B2 (en) 2017-07-28 2021-09-14 Snap Inc. Software application manager for messaging applications
US10586368B2 (en) 2017-10-26 2020-03-10 Snap Inc. Joint audio-video facial animation system
US11460974B1 (en) 2017-11-28 2022-10-04 Snap Inc. Content discovery refresh
US10726603B1 (en) 2018-02-28 2020-07-28 Snap Inc. Animated expressive icon
US10979752B1 (en) 2018-02-28 2021-04-13 Snap Inc. Generating media content items based on location information
US11310176B2 (en) 2018-04-13 2022-04-19 Snap Inc. Content suggestion system
US11030813B2 (en) 2018-08-30 2021-06-08 Snap Inc. Video clip object tracking
US10895964B1 (en) 2018-09-25 2021-01-19 Snap Inc. Interface to display shared user groups
US10904181B2 (en) 2018-09-28 2021-01-26 Snap Inc. Generating customized graphics having reactions to electronic message content
US10698583B2 (en) 2018-09-28 2020-06-30 Snap Inc. Collaborative achievement interface
US11245658B2 (en) 2018-09-28 2022-02-08 Snap Inc. System and method of generating private notifications between users in a communication session
US11189070B2 (en) 2018-09-28 2021-11-30 Snap Inc. System and method of generating targeted user lists using customizable avatar characteristics
US10872451B2 (en) 2018-10-31 2020-12-22 Snap Inc. 3D avatar rendering
US11176737B2 (en) 2018-11-27 2021-11-16 Snap Inc. Textured mesh building
US10861170B1 (en) 2018-11-30 2020-12-08 Snap Inc. Efficient human pose tracking in videos
US11199957B1 (en) 2018-11-30 2021-12-14 Snap Inc. Generating customized avatars based on location information
US11516173B1 (en) 2018-12-26 2022-11-29 Snap Inc. Message composition interface
US11294936B1 (en) 2019-01-30 2022-04-05 Snap Inc. Adaptive spatial density based clustering
US10936066B1 (en) 2019-02-13 2021-03-02 Snap Inc. Sleep detection in a location sharing system
US10852918B1 (en) 2019-03-08 2020-12-01 Snap Inc. Contextual information in chat
US11188190B2 (en) 2019-06-28 2021-11-30 Snap Inc. Generating animation overlays in a communication session
US11676199B2 (en) 2019-06-28 2023-06-13 Snap Inc. Generating customizable avatar outfits
US11307747B2 (en) 2019-07-11 2022-04-19 Snap Inc. Edge gesture interface with smart interactions
US11455081B2 (en) 2019-08-05 2022-09-27 Snap Inc. Message thread prioritization interface
US11320969B2 (en) 2019-09-16 2022-05-03 Snap Inc. Messaging system with battery level sharing
US11080917B2 (en) 2019-09-30 2021-08-03 Snap Inc. Dynamic parameterized user avatar stories
US11218838B2 (en) 2019-10-31 2022-01-04 Snap Inc. Focused map-based context information surfacing
US11063891B2 (en) 2019-12-03 2021-07-13 Snap Inc. Personalized avatar notification
US11128586B2 (en) 2019-12-09 2021-09-21 Snap Inc. Context sensitive avatar captions
US11227442B1 (en) 2019-12-19 2022-01-18 Snap Inc. 3D captions with semantic graphical elements
US11263817B1 (en) 2019-12-19 2022-03-01 Snap Inc. 3D captions with face tracking
US11169658B2 (en) 2019-12-31 2021-11-09 Snap Inc. Combined map icon with action indicator
US11356720B2 (en) 2020-01-30 2022-06-07 Snap Inc. Video generation system to render frames on demand
US11036781B1 (en) 2020-01-30 2021-06-15 Snap Inc. Video generation system to render frames on demand using a fleet of servers
US11217020B2 (en) 2020-03-16 2022-01-04 Snap Inc. 3D cutout image modification
US11625873B2 (en) 2020-03-30 2023-04-11 Snap Inc. Personalized media overlay recommendation
US11818286B2 (en) 2020-03-30 2023-11-14 Snap Inc. Avatar recommendation and reply
US11580682B1 (en) 2020-06-30 2023-02-14 Snap Inc. Messaging system with augmented reality makeup
US11360733B2 (en) 2020-09-10 2022-06-14 Snap Inc. Colocated shared augmented reality without shared backend
US11452939B2 (en) 2020-09-21 2022-09-27 Snap Inc. Graphical marker generation system for synchronizing users
US11615592B2 (en) 2020-10-27 2023-03-28 Snap Inc. Side-by-side character animation from realtime 3D body motion capture
US11544885B2 (en) 2021-03-19 2023-01-03 Snap Inc. Augmented reality experience based on physical items
US11636654B2 (en) 2021-05-19 2023-04-25 Snap Inc. AR-based connected portal shopping
US11673054B2 (en) 2021-09-07 2023-06-13 Snap Inc. Controlling AR games on fashion items
US11663792B2 (en) 2021-09-08 2023-05-30 Snap Inc. Body fitted accessory with physics simulation
US11734866B2 (en) 2021-09-13 2023-08-22 Snap Inc. Controlling interactive fashion based on voice
US11636662B2 (en) 2021-09-30 2023-04-25 Snap Inc. Body normal network light and rendering control
US11790614B2 (en) 2021-10-11 2023-10-17 Snap Inc. Inferring intent from pose and speech input
US11651572B2 (en) 2021-10-11 2023-05-16 Snap Inc. Light and rendering of garments
US11823346B2 (en) 2022-01-17 2023-11-21 Snap Inc. AR body part tracking system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150345A1 (en) * 1993-09-28 1995-04-06 Makoto Komatsu Quinoxaline derivative as antidiabetic agent
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
SK1212002A3 (en) * 1999-07-29 2002-11-06 Egyt Gyogyszervegyeszeti Gyar Isoquinoline derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance
CA2386474A1 (en) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
DE10115994A1 (de) * 2001-03-30 2002-10-10 Wella Ag (p-Amino-hydroxyphenyl)acrylamid-Derivate und diese Verbindungen enthaltende Färbemittel
HUP0401750A2 (hu) * 2001-05-31 2004-12-28 Bristol-Myers Squibb Company Cinnamidszármazékok mint KCNQ káliumcsatorna-modulátorok és ezeket tartalmazó gyógyszerkészítmények
DE20110355U1 (de) * 2001-06-22 2001-08-30 Wella Ag, 64295 Darmstadt (Dihydroxyphenyl)-acrylamid-Derivate und diese Verbindungen enthaltende Färbemittel

Also Published As

Publication number Publication date
US20050020661A1 (en) 2005-01-27
US20030199553A1 (en) 2003-10-23
WO2003072570A1 (en) 2003-09-04
AU2003206028A1 (en) 2003-09-09
BR0300314A (pt) 2004-09-08
US6821977B2 (en) 2004-11-23
CA2419685A1 (en) 2003-08-28
JP2004002311A (ja) 2004-01-08
EP1340500A1 (en) 2003-09-03

Similar Documents

Publication Publication Date Title
MXPA03000966A (es) Agentes antidiabeticos.
SI1555267T1 (sl) 2,3-DIHIDRO-6-NITROIMIDAZO(2,1-b)OKSAZOLI
DE60302150D1 (en) N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren
AU2003286867A8 (en) E.x.o. rimwear
IL159152A0 (en) 3-fluoro-pyrrolidines as antidiabetic agents
HK1078568A1 (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
ZA200307420B (en) Point chisel.
MXPA03007695A (es) Placa de teclas.
AU2003290818A8 (en) Topoisomerase-targeting agents
AU2003215804A1 (en) Antidiabetic agents
SG116498A1 (en) Cleaning tool.
AU2003215803A1 (en) Antidiabetic agents
GB0202011D0 (en) The Fucker
GB0218515D0 (en) S.d.s.
EG23241A (en) Beshob.
ZA200408169B (en) Imidazolinylmethyl aralkylsulfonamides.
MXPA02003350A (es) Calentador-tanque-termo-solar.
MXPA02001688A (es) Marco facil.
GB0209707D0 (en) Bidfor100.com
ZA200207924B (en) Combination tool.
GB0215256D0 (en) I.t
GB0212492D0 (en) D.I.Y. workvest
GB0204798D0 (en) Cycostatic agents
ZA200307195B (en) Mechanical tools.
ZA200304737B (en) A combination.